Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AVACTA GROUP PLC

Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers INO LSE
Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts
From AVACTA GROUP PLC
Via GlobeNewswire
Tickers LSE
Avacta Announces Agreement to Sell Launch Diagnostics and a Corporate Update
From AVACTA GROUP PLC
Via GlobeNewswire
Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers
From AVACTA GROUP PLC
Via GlobeNewswire
Avacta Appoints Brian Hahn as Chief Financial Officer
From AVACTA GROUP PLC
Via GlobeNewswire
Avacta Announces Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study
From Avacta Group plc
Via Business Wire
First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study
From Avacta Group plc
Via Business Wire
Avacta Opens First Two US Clinical Investigator Sites for AVA6000 Phase 1 Clinical Study
From Avacta Group plc
Via Business Wire
Avacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
From Avacta Group plc
Via Business Wire
Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division
From Avacta Group plc
Via Business Wire
Avacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual Meeting
From Avacta Group plc
Via Business Wire
Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study
From Avacta Group plc
Via Business Wire
Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration
From Avacta Group plc
Via Business Wire
Avacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth Cohort
From Avacta Group plc
Via Business Wire
LG Chem Renews License Triggering Payment to Avacta
From Avacta Group plc
Via Business Wire
AffyXell Expands its Strategic Partnership With GenScript ProBio
From Avacta Group plc
Via Business Wire
Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake
From Avacta Group plc
Via Business Wire
Avacta Appoints Dr Christina Coughlin as Non-Executive Director
From Avacta Group plc
Via Business Wire
Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin
From Avacta Group plc
Via Business Wire
Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development
From Avacta Group plc
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.